Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study

Archives of Internal Medicine

Volumn 161, Issue 16, 2001, Pages 1962-1968

  Nieuwkerk, Pythia T ^a   Sprangers, Mirjam A G ^a   Burger, David M ^b   Hoetelmans, Richard M W ^c   Hugen, Patricia W H ^b   Danner, Sven A ^a   Van Der Ende, Marchina E ^d   Schneider, Margriet M E ^e   Schrey, Gerrit ^f   Meenhorst, Pieter L ^c   Sprenger, Herman G ^g   Kauffmann, Robert H ^h   Jambroes, Marielle ^a   Chesney, Margaret A ⁱ   De Wolf, Frank ^a   Lange, Joep M A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Utrecht Medical Center   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h LEYENBURG HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG EFFICACY; NETHERLANDS; QUESTIONNAIRE; TIME;

EID: 0035955898     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.16.1962     Document Type: Article

References (29)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
3. Predictors of self-reported adherence and plasma HIV, concentrations in patients on multidrug antiretroviral regimens
4. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
5. How much adherence is enough? a prospective study of adherence to protease inhibitor therapy using MEMSCaps
6. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
7. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
8. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
9. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
10. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance therapy
11. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
12. Simultaneous determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reverse-phase high-performance liquid chromatography
13. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection
14. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection
15. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
16. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
17. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
18. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC
19. Antiretroviral therapy for HIV infection in 1997
20. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
21. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
22. Virological response to protease inhibitor therapy in an HIV clinic cohort
23. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
24. Adherence: A necessity for successful HIV combination therapy
25. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy
26. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
27. Urological complaints in relation to indinavir plasma concentrations in HIV-1 infected patients
28. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM Study